In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has...
In a significant development in the field of thoracic oncology, recent findings from the Phase 3 E4512 clinical trial have...
In a groundbreaking advancement for the management of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)...
In a groundbreaking advancement within the realm of targeted oncology, the international cancer research community has witnessed compelling evidence supporting...
Groundbreaking Phase III Trial Demonstrates Superior Efficacy of Aumolertinib Plus Chemotherapy in Advanced EGFR-Mutant NSCLC In a pivotal advancement for...
In a groundbreaking development presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on...
In a groundbreaking advancement for the treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations,...
In a groundbreaking development in the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)...
In a groundbreaking development presented at the prestigious International Association for the Study of Lung Cancer 2025 World Conference on...
In recent years, the intricate relationship between the human microbiome and cancer development has emerged as a focal point of...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine